Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
J Pediatr Surg ; 49(1): 39-45; discussion 45, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24439578

ABSTRACT

PURPOSE: Pulmonary hypertension (pHTN), a main determinant of survival in congenital diaphragmatic hernia (CDH), results from in utero vascular remodeling. Phosphodiesterase type 5 (PDE5) inhibitors have never been used antenatally to treat pHTN. The purpose of this study is to determine if antenatal PDE5 inhibitors can prevent pHTN in the fetal lamb model of CDH. METHODS: CDH was created in pregnant ewes. Postoperatively, pregnant ewes received oral placebo or tadalafil, a PDE5 inhibitor, until delivery. Near term gestation, lambs underwent resuscitations, and lung tissue was snap frozen for protein analysis. RESULTS: Mean cGMP levels were 0.53±0.11 in placebo-treated fetal lambs and 1.73±0.21 in tadalafil-treated fetal lambs (p=0.002). Normalized expression of eNOS was 82%±12% in Normal-Placebo, 61%±5% in CDH-Placebo, 116%±6% in Normal-Tadalafil, and 86%±8% in CDH-Tadalafil lambs. Normalized expression of ß-sGC was 105%±15% in Normal-Placebo, 82%±3% in CDH-Placebo, 158%±16% in Normal-Tadalafil, and 86%±8% in CDH-Tadalafil lambs. Endothelial NOS and ß-sGC were significantly decreased in CDH (p=0.0007 and 0.01 for eNOS and ß-sGC, respectively), and tadalafil significantly increased eNOS expression (p=0.0002). CONCLUSIONS: PDE5 inhibitors can cross the placental barrier. ß-sGC and eNOS are downregulated in fetal lambs with CDH. Antenatal PDE5 inhibitors normalize eNOS and may prevent in utero vascular remodeling in CDH.


Subject(s)
Carbolines/therapeutic use , Fetal Diseases/drug therapy , Fetal Therapies , Hernias, Diaphragmatic, Congenital , Nitric Oxide Synthase Type III/biosynthesis , Phosphodiesterase 5 Inhibitors/therapeutic use , Animals , Carbolines/administration & dosage , Carbolines/pharmacology , Cyclic GMP/analysis , Disease Models, Animal , Drug Evaluation, Preclinical , Enzyme Induction/drug effects , Female , Hernia, Diaphragmatic/complications , Hernia, Diaphragmatic/embryology , Hernia, Diaphragmatic/enzymology , Hernia, Diaphragmatic/prevention & control , Hypertension, Pulmonary/embryology , Hypertension, Pulmonary/enzymology , Hypertension, Pulmonary/etiology , Hypertension, Pulmonary/prevention & control , Hypertrophy, Right Ventricular/embryology , Hypertrophy, Right Ventricular/enzymology , Hypertrophy, Right Ventricular/etiology , Lung/chemistry , Lung/drug effects , Lung/embryology , Lung/pathology , Maternal-Fetal Exchange , Nitric Oxide Synthase Type III/genetics , Organ Size/drug effects , Phosphodiesterase 5 Inhibitors/administration & dosage , Phosphodiesterase 5 Inhibitors/pharmacology , Pregnancy , Random Allocation , Second Messenger Systems/drug effects , Sheep , Tadalafil
2.
Pediatr Cardiol ; 34(8): 2030-3, 2013.
Article in English | MEDLINE | ID: mdl-23179424

ABSTRACT

Uncontrolled/untreated maternal hyperthyroidism has been associated with fetal tachycardia. We report a case of right-ventricular (RV) hypertrophy with pericardial effusion related to untreated maternal Graves' disease. A 33-year-old G4P1021 woman with uncontrolled Graves' disease presented at 29 weeks gestation with abdominal pain and vaginal bleeding. Fetal echocardiogram showed severe RV hypertrophy and a pericardial effusion. The infant was born prematurely, and initial transthoracic echocardiogram showed severe RV hypertrophy and a small pericardial effusion. The infant had clinical findings consistent with congenital thyrotoxicosis and was treated for this. Follow-up imaging at 4 weeks showed improvement of the cardiac hypertrophy and pericardial effusion. This article describes the presentation of fetal RV hypertrophy with congenital thyrotoxicosis and underscores the importance of screening for this prenatally in mothers with uncontrolled or untreated hyperthyroidism.


Subject(s)
Hyperthyroidism/complications , Hypertrophy, Right Ventricular/etiology , Infant, Premature, Diseases/etiology , Pericardial Effusion/etiology , Pregnancy Complications , Adult , Echocardiography , Female , Follow-Up Studies , Humans , Hyperthyroidism/blood , Hypertrophy, Right Ventricular/diagnostic imaging , Hypertrophy, Right Ventricular/embryology , Infant, Newborn , Infant, Premature , Infant, Premature, Diseases/diagnostic imaging , Male , Pericardial Effusion/diagnostic imaging , Pericardial Effusion/embryology , Pregnancy , Prenatal Exposure Delayed Effects , Thyrotropin/blood , Ultrasonography, Prenatal
3.
Ginekol Pol ; 83(2): 145-8, 2012 Feb.
Article in Polish | MEDLINE | ID: mdl-22568362

ABSTRACT

The use of fenoterol in the treatment of preterm labor is associated with the risk of many complications in the mother and the fetus. We present a case of a multipara treated with oral fenoterol due to threatening preterm labor 14 weeks. At 35 weeks of gestation the fetus was diagnosed with hypertrophic cardiomyopathy with severe impairment of the right ventricle. The only factor that might have caused such a state of the fetal circulatory system was fenoterol, used from 21 weeks of gestation. After the withdrawal of the fenoterol the fetal right ventricular function improved gradually. However fetal cardiac hypertrophy persisted until the birth at 39 weeks of gestation. Concentric hypertrophy of the right ventricular wall and interventricular septum were confirmed in the newborn.


Subject(s)
Adrenergic beta-2 Receptor Agonists/adverse effects , Cardiomyopathy, Hypertrophic/chemically induced , Fenoterol/adverse effects , Fetal Diseases/chemically induced , Hypertrophy, Right Ventricular/chemically induced , Hypertrophy, Right Ventricular/embryology , Tocolytic Agents/adverse effects , Administration, Oral , Adrenergic beta-2 Receptor Agonists/administration & dosage , Adult , Cardiomyopathy, Hypertrophic/diagnostic imaging , Female , Fenoterol/administration & dosage , Fetal Diseases/diagnostic imaging , Humans , Hypertrophy, Right Ventricular/diagnostic imaging , Infant, Newborn , Obstetric Labor, Premature/drug therapy , Pregnancy , Tocolytic Agents/administration & dosage , Ultrasonography, Prenatal
4.
Congenit Heart Dis ; 6(1): 51-6, 2011.
Article in English | MEDLINE | ID: mdl-21269413

ABSTRACT

OBJECTIVE: Prenatal constriction of the ductus arteriosus associated with maternal drug ingestion was reported several decades ago. There are fewer reports of the complete closure of the ductus arteriosus; therefore, the clinical features of the latter are poorly understood. The aim of this study is to clarify the clinical features of complete ductal closure and postnatal pulmonary hypertension by performing echocardiography of the fetus. PATIENTS: We diagnosed four fetuses with complete ductal closure by performing fetal echocardiography and reviewed the prenatal and postnatal medical records of the mother and fetus. RESULTS: One mother each had bronchial asthma, ulcerative colitis, and idiopathic thrombocytopenic purpura, and they had received nonsteroidal anti-inflammatory drugs and/or corticosteroids during pregnancy. The fourth mother did not have basal disease and had not ingested any drugs. Fetal diagnosis was performed at 32-38 weeks of gestation. All fetuses had right heart dilatation with tricuspid regurgitation in the absence of any cardiac defects, and Doppler echocardiography indicated that the right ventricular pressure was elevated. Two of the fetuses had fetal hydrops, which suggested severe right heart dysfunction. All fetuses were delivered by emergent cesarean delivery. After birth, all the infants developed persistent pulmonary hypertension and required oxygen inhalation. Of these, three required mechanical ventilation, and two, nitric oxide inhalation. All infants improved within 2 weeks, and they had no neurological and cardiac complications after discharge. CONCLUSION: Right heart dilatation and severe tricuspid regurgitation in the absence of a cardiac defect in the fetus strongly suggested ductal dysfunction. Careful evaluation of ductal patency and right ventricular function can lead to precise early diagnosis and good prognosis.


Subject(s)
Adrenal Cortex Hormones/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Ductus Arteriosus/drug effects , Fetal Heart/drug effects , Adult , Cesarean Section , Constriction, Pathologic , Ductus Arteriosus/diagnostic imaging , Ductus Arteriosus/embryology , Echocardiography, Doppler , Female , Fetal Heart/diagnostic imaging , Gestational Age , Humans , Hydrops Fetalis/chemically induced , Hydrops Fetalis/physiopathology , Hydrops Fetalis/therapy , Hypertrophy, Right Ventricular/chemically induced , Hypertrophy, Right Ventricular/diagnostic imaging , Hypertrophy, Right Ventricular/embryology , Hypertrophy, Right Ventricular/therapy , Infant, Newborn , Maternal Exposure , Persistent Fetal Circulation Syndrome/chemically induced , Persistent Fetal Circulation Syndrome/therapy , Pregnancy , Treatment Outcome , Tricuspid Valve Insufficiency/chemically induced , Tricuspid Valve Insufficiency/diagnostic imaging , Tricuspid Valve Insufficiency/embryology , Tricuspid Valve Insufficiency/therapy , Ultrasonography, Prenatal , Young Adult
5.
Ultrasound Obstet Gynecol ; 23(5): 517-9, 2004 May.
Article in English | MEDLINE | ID: mdl-15133807

ABSTRACT

Constriction of the ductus arteriosus in the fetus is well studied, but mostly secondary to maternal exposure to indomethacin or other non-steroidal anti-inflammatory medications, or structural cardiac lesions. We present a case of a fetus presenting with right ventricular hypertrophy secondary to an S-shaped ductus arteriosus with distal constriction diagnosed by pulsed Doppler imaging. A review of the recent English literature of similar cases is presented.


Subject(s)
Ductus Arteriosus/diagnostic imaging , Fetal Diseases/diagnostic imaging , Hypertrophy, Right Ventricular/diagnostic imaging , Adult , Constriction, Pathologic/complications , Constriction, Pathologic/diagnostic imaging , Constriction, Pathologic/embryology , Ductus Arteriosus/pathology , Echocardiography, Doppler, Pulsed , Female , Fetal Diseases/etiology , Humans , Hypertrophy, Right Ventricular/embryology , Hypertrophy, Right Ventricular/etiology , Pregnancy , Ultrasonography, Prenatal
SELECTION OF CITATIONS
SEARCH DETAIL
...